Guggenheim initiated coverage on Metsera with a new price target
$MTSR
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2025 | $56.00 | Buy | Guggenheim |
| 2/25/2025 | $38.00 | Buy | BofA Securities |
| 2/25/2025 | Outperform | Evercore ISI |
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT. A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientif
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
8-K - Metsera, Inc. (0002040807) (Filer)
SCHEDULE 13G - Metsera, Inc. (0002040807) (Subject)
SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb
Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00
BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00
Evercore ISI initiated coverage of Metsera with a rating of Outperform